---
title: "Aspire Biopharma Holdings, Inc. (ASBP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ASBP.US.md"
symbol: "ASBP.US"
name: "Aspire Biopharma Holdings, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:16:41.210Z"
locales:
  - [en](https://longbridge.com/en/quote/ASBP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASBP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASBP.US.md)
---

# Aspire Biopharma Holdings, Inc. (ASBP.US)

## Company Overview

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [aspirebiolabs.com](https://aspirebiolabs.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.55)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 103 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 30.89% |  |
| P/B Ratio | 2.09 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8089366.44 |  |
| Revenue | 34555.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 762.73% | A |
| Profit Margin | -34039.68% | E |
| Gross Margin | 20.28% | D |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 30.89% | B |
| Total Assets YoY | 262.10% | A |
| Net Assets YoY | 155.64% | A |
| Cash Flow Margin | 52.80% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 45.65% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Aspire Biopharma Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "30.89%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.09",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8089366.44",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "34555.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "762.73%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-34039.68%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "20.28%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "30.89%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "262.10%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "155.64%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "52.80%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "45.65%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.60 | 90/190 | - | - | - |
| PB | 1.83 | 83/190 | - | - | - |
| PS (TTM) | 204.31 | 155/190 | 5310.18 | 2531.16 | 591.55 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ASBP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ASBP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ASBP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ASBP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**